Patient Advocate Says Novartis $475,000 Breakthrough Should Cost Just $160,000

Feb 8, 2018, 15:04 by Michael Croft

Forbes | David Mitchell, 67, says he's sure that Novartis' Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He's sure of something else, too: Novartis is charging too much.

February 08, 2018 | David Mitchell, 67, says he's sure that Novartis' Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He's sure of something else, too: Novartis is charging too much. Forbes